Jaguar Health IncNASDAQ:JAGX
- LAST PRICE1.0200
- TODAY'S CHANGE (%)-0.0200 (-1.9231%)
- Bid / Lots1.0100/ 14
- Ask / Lots1.0300/ 10
- Open / Previous Close1.0400 / 1.0400
- Day Range
- 52 Week Range
- Volume130,967
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | JAGX |
|---|---|---|
| 09:32 ET | 13459 | 1.03 |
| 09:33 ET | 1202 | 1.05 |
| 09:35 ET | 5407 | 1.07 |
| 09:37 ET | 1839 | 1.06 |
| 09:39 ET | 1415 | 1.06 |
| 09:42 ET | 822 | 1.0625 |
| 09:46 ET | 830 | 1.06 |
| 09:48 ET | 200 | 1.0514 |
| 09:50 ET | 300 | 1.05 |
| 09:55 ET | 320 | 1.069 |
| 09:57 ET | 384 | 1.06 |
| 10:02 ET | 100 | 1.0507 |
| 10:04 ET | 805 | 1.0595 |
| 10:06 ET | 500 | 1.04 |
| 10:08 ET | 600 | 1.05 |
| 10:09 ET | 1610 | 1.045 |
| 10:11 ET | 7228 | 1.04 |
| 10:13 ET | 1000 | 1.0395 |
| 10:20 ET | 110 | 1.03 |
| 10:22 ET | 400 | 1.0399 |
| 10:24 ET | 1100 | 1.03 |
| 10:26 ET | 2890 | 1.03 |
| 10:31 ET | 600 | 1.0305 |
| 10:36 ET | 28641 | 1.03 |
| 10:38 ET | 2610 | 1.02 |
| 10:44 ET | 540 | 1.03 |
| 10:47 ET | 200 | 1.025 |
| 10:49 ET | 650 | 1.0205 |
| 10:51 ET | 1011 | 1.0205 |
| 10:56 ET | 200 | 1.0298 |
| 11:00 ET | 243 | 1.0218 |
| 11:02 ET | 120 | 1.02 |
| 11:03 ET | 7485 | 1.03 |
| 11:05 ET | 1947 | 1.0305 |
| 11:07 ET | 155 | 1.0399 |
| 11:09 ET | 300 | 1.03 |
| 11:18 ET | 236 | 1.0313 |
| 11:20 ET | 7423 | 1.03 |
| 11:21 ET | 2440 | 1.025 |
| 11:25 ET | 200 | 1.0209 |
| 11:27 ET | 1800 | 1.02 |
| 11:30 ET | 1000 | 1.025 |
| 11:34 ET | 321 | 1.02 |
| 11:36 ET | 762 | 1.0201 |
| 11:39 ET | 376 | 1.0234 |
| 11:50 ET | 200 | 1.0266 |
| 11:56 ET | 100 | 1.025 |
| 12:03 ET | 100 | 1.0209 |
| 12:08 ET | 1000 | 1.02 |
| 12:10 ET | 1100 | 1.03 |
| 12:12 ET | 500 | 1.03 |
| 12:14 ET | 185 | 1.022 |
| 12:26 ET | 200 | 1.02 |
| 12:28 ET | 100 | 1.0279 |
| 12:30 ET | 998 | 1.02 |
| 12:32 ET | 200 | 1.015 |
| 12:35 ET | 220 | 1.01 |
| 12:37 ET | 250 | 1.015 |
| 12:46 ET | 100 | 1.015 |
| 12:48 ET | 5800 | 1.03 |
| 12:57 ET | 145 | 1.02 |
| 01:02 ET | 1038 | 1.0241 |
| 01:08 ET | 300 | 1.02 |
| 01:09 ET | 200 | 1.02 |
| 01:15 ET | 300 | 1.02 |
| 01:18 ET | 300 | 1.02 |
| 01:20 ET | 100 | 1.02 |
| 01:31 ET | 760 | 1.02 |
| 01:33 ET | 306 | 1.02 |
| 01:36 ET | 100 | 1.02 |
| 01:42 ET | 100 | 1.02 |
Today
Nov 22, 2024
Nov 19, 2024
Jaguar Health Family Company Napo Therapeutics Named "Best Pharmaceuticals Innovator of the Year - Europe", from 9:31AM ET on Tuesday Nov 19, 2024 by Dow Jones
9:31AM ET on Tuesday Nov 19, 2024 by Dow Jones
Nov 13, 2024
Jaguar Health Reports Third Quarter 2024 Financial Results, from 8:02AM ET on Wednesday Nov 13, 2024 by Dow Jones
8:02AM ET on Wednesday Nov 13, 2024 by Dow Jones
Nov 11, 2024
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Jaguar Health Inc | 9.6M | -0.1x | --- |
Syros Pharmaceuticals Inc | 7.9M | -0.1x | --- |
BioNexus Gene Lab Corp | 5.2M | -6.8x | --- |
Aspira Women's Health Inc | 12.0M | -0.5x | --- |
LakeShore Biopharma Co Ltd | 50.0M | -0.5x | --- |
Spruce Biosciences Inc | 20.0M | -0.5x | --- |
Company Information
Jaguar Health, Inc. is a commercial-stage pharmaceuticals company. The Company is focused on developing novel proprietary prescription medicines sustainably derived from plants from rainforest areas for people and animals with gastrointestinal distress. It operates through two segments: human health and animal health. The animal health segment is focused on developing and commercializing prescription and non-prescription products for companion and production animals. The human health segment is focused on developing and commercializing of human products and the ongoing commercialization of Mytesi, which is used for the symptomatic relief of non-infectious diarrhea in adults with human immunodeficiency virus (HIV)/ acquired immunodeficiency syndrome (AIDS) on antiretroviral therapy. The Canalevia-CA1 is for the treatment of chemotherapy-induced diarrhea (CID) in dogs. Its subsidiary Napo Pharmaceuticals, Inc. focuses on developing and commercializing human prescription pharmaceuticals.
Contact Information
- Headquarters
- 200 PINE STREET SUITE 400SAN FRANCISCO, CA, United States 94104
- Phone
- 415-371-8300
- Fax
- 302-655-5049
Executives
- Independent Chairman of the Board
- James Bochnowski
- President, Chief Executive Officer, Director
- Lisa Conte
- Chief Financial Officer
- Carol Lizak
- Chief Scientific Officer
- Pravin Chaturvedi
- Chief of Staff, General Counsel, Chief Compliance Officer
- Jonathan Wolin
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $9.6M |
|---|---|
Revenue (TTM) | $10.5M |
Shares Outstanding | 9.2M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.90 |
EPS | $-19.89 |
Book Value | $4.05 |
P/E Ratio | -0.1x |
Price/Sales (TTM) | 0.9 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -276.58% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
